Carmot Therapeutics stock

Carmot Therapeutics Stock

HealthTech

Looking to sell Carmot Therapeutics stock or options?

Founded: 2008Funding to Date: $372Mhttps://www.carmot.us

Carmot Therapeutics Inc, a clinical-stage biotech firm, is committed to creating transformative treatments for individuals suffering from metabolic disorders such as obesity and diabetes. The company has three clinical-stage product candidates in its pipeline: CT-388, a once-weekly injectable dual GLP-1/GIP receptor agonist for combating obesity and type 2 diabetes (T2D); CT-996, a once-daily oral small molecule GLP-1 receptor agonist also aimed at treating obesity and T2D; and CT-868, a once-daily injectable dual GLP-

Investors Include:

5AM Ventures, Ponoi Capital, TCG Crossover Management, Michael J. Fox Foundation, Amgen, RA Capital Management, Millennium Management, National Science Foundation, Willett Advisors, Venrock, National Cancer Institute, Franklin Templeton, Deep Track Capital, Janus Henderson Investors, Horizons Ventures, QB3, The Column Group, Qualifying Therapeutic Discovery Project, Jerome Dahan, Frazier Lifesciences Acquisition.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more